Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m (→References) |
||
| Line 21: | Line 21: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Combination drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Liposomal chemotherapy]] | [[Category:Liposomal chemotherapy]] | ||
Revision as of 22:04, 22 March 2022
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. [1][2][3]
Route: IV
Extravasation: no information
Disease for which it is used
History of changes in FDA indication
- 8/3/2017: Granted FDA regular approval for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. (Based on CLTR0310-301)
Patient Information
Also known as
- Code name: CPX-351
- Brand name: Vyxeos